Pharmacogenomic Prospects Explored for Pain Management

As much as 40% to 60% of the general population has phenotype variability

The following article features coverage from PAINWeek 2017 in Las Vegas, Nevada. Click here to read more of MPR's conference coverage.

LAS VEGAS — During their presentation at PAINWeek 2017, taking place September 5-9, Jeffrey Fudin, PharmD, and Timothy Atkinson, PharmD, BCPS, CPE, provided an overview of how pharmacogenetics may be leveraged for optimal pain management.1 The presenters summarized known links between certain pharmacogenetic variants and responses to pain medications, presented cases in which pharmacogenetics may be useful, and demonstrated how an individualized pain management plan may be crafted based on a patient's pharmacogenetic profile.

Guidelines pertaining to pharmacogenetics have been developed by the Clinical Pharmacogenetics Implementation Consortium of the National Institutes of Health Pharmacogenomics Research Network, a group established “to catalyze and lead research in precision medicine for the discovery and translation of genomic variation influencing therapeutic and adverse drug effects,” and the pharmacogenomics resource PharmGKB.2

As much as 40% to 60% of the general population has phenotype variability, and such genetic differences are thought to have an effect on a patient's response to 25% of all drugs. Clinical applications of pharmacogenetics are largely dominated by polymorphisms of cytochrome P450 (CYP450) enzymes that are involved, among other functions, in the metabolism of opiates (eg, in phase 1 metabolism [CYP2D6 for codeine, hydrocodone, oxycodone, and tramadol; CYP2C19 for methadone; CYP3A4 for tramadol] and in phase 2 metabolism [uridine 5'-diphospho-glucuronosyltransferase (UGT) UGT2B7 and UGT2B15 for morphine, oxymorphone, hydromorphone, and tapentadol]).3,4

Although various allele variants for these and other enzymes have been associated with poor, intermediate, extensive, or ultrarapid metabolizers of certain medications, the use of pharmacogenetics in clinical practice currently faces several challenges. Dr Fudin cited the absence of a current “universal definition” of processes that would allow the interpretation of genotyping and its translation into adequate clinical actions, the lack of recommended associations between drugs and gene pairs, resistance by clinicians to adopt such information, and still prohibitive costs.2

Related Articles

Dr Atkinson provided scenarios in which pharmacogenetic tests need not be performed. For example, for some CYP2D6 variants, only the ultrarapid and poor metabolizers were shown to display a significant effect on dosing, and the latter may require a higher dose of pain medications, which is a rare occurrence. In addition, some CYP2D6 variants only have a minor impact on minor active metabolites and a profound effect only on weak opioids and prodrugs. Polymorphisms in the μ-opioid receptor gene OPRM1 were shown to have a profound effect solely on weak opioids and prodrugs.

In an editorial coauthored by Drs Fudin and Atkinson, the clinicians insist that “pharmacogenomic testing for crucial metabolic pathways should enable prediction of clinical drug response, especially when targeted binding sites or tissues are being considered.”5

Disclosures

Dr Fudin serves as a consultant and as an advisory board member for several pharmaceutical companies including AstraZeneca and DepoMed. Dr Atkinson serves as a consultant for Axial Healthcare.

Read more of MPR's coverage of PAINWeek 2017 by visiting the conference page